No symptom reliably tells a patient that her etonogestrel implant has stopped working. The only dependable marker of remaining contraceptive cover is the documented insertion date, read against the labeled duration of use. Bleeding changes, cramping, acne, or mood shifts are common throughout the life of the implant and do not track falling hormone release in any usable way.
That single point resolves most of the questions clinics field about the signs Nexplanon is wearing off. It also redirects the visit toward what actually matters: confirming the device is in place, checking the replacement date, reviewing interacting medications, and testing when pregnancy is plausible. The sections below work through that sequence in the order a clinician would.
The Short Version
- Duration is clock-based, not symptom-based. Insertion date governs replacement, not how the patient feels.
- Bleeding patterns are unpredictable from day one. A change in year three means little on its own.
- Three scenarios warrant real concern: a non-palpable implant, enzyme-inducing drug therapy, and an overdue device.
- Pregnancy symptoms warrant a test, with ectopic pregnancy kept in the differential.
- Fertility returns quickly after removal, so bridging contraception should be discussed before the device comes out.
What Patients Mean by Signs Nexplanon Is Wearing Off
Patients usually describe one of four changes: periods returning after months of amenorrhea, heavier or longer bleeding, new cramping that feels ovulatory, or shifts in acne, libido, and mood. Each is plausible as a hormonal effect. None has been validated as a marker of waning efficacy.
The prescribing information describes a wide and shifting range of bleeding patterns across the whole period of use. Roughly one in five users report no bleeding at all, while infrequent bleeding is the single most common pattern. Prolonged or frequent bleeding also occurs and is the leading reason users ask for early removal. Importantly, the pattern an individual settles into in the first months does not predict what happens later, and a change does not signal that the device has run out.
Hormone release does decline. Etonogestrel delivery is highest in the first weeks after insertion and falls gradually across the labeled period. That decline is built into the dosing design, and serum concentrations are intended to stay above the level associated with ovulation suppression for the full labeled duration. In other words, falling release is expected and is not itself evidence of failure.
Why it matters: Treating symptom reports as proof of expiry leads to unnecessary early removals and avoidable gaps in cover.
How Long the Implant Is Labeled to Last
The single-rod etonogestrel 68 mg implant is approved in the United States for prevention of pregnancy for up to three years, after which the device should be removed and may be replaced. The three-year clock begins at insertion, not at the point the patient first noticed a change in bleeding. Published failure rates are consistently below one pregnancy per 100 users per year, placing it among the most effective reversible methods available.
There is published evidence examining contraceptive effect beyond three years, and some professional guidance acknowledges it. Extended use past the labeled interval is off-label in the US. If a clinic discusses it, the conversation should be documented as off-label, grounded in current guidance, and never presented as the approved duration. Full labeling for the product is available through the FDA’s official labeling repository.
Is there such a thing as expired implant symptoms?
No. A device past its replacement date does not produce a recognizable symptom cluster. Patients searching for expired implant symptoms are usually describing ordinary bleeding variation, or a pregnancy that has already occurred for a separate reason. The practical answer in clinic is a date check and, where relevant, a pregnancy test.
Note that two different expiry concepts get confused. The carton carries a sterile-product expiration date that governs whether a clinic may insert that unit. The three-year interval governs how long an inserted device remains labeled for use. They are unrelated, and both belong in the chart.
When Contraceptive Efficacy Is Genuinely in Question
A small number of situations deserve active investigation rather than reassurance. These are the real-world answers when a patient asks how to know if the implant is not working.
- The implant cannot be palpated. This raises the possibility of deep placement, migration, or a failed insertion.
- Enzyme-inducing medication was started. Serum etonogestrel can fall during concurrent therapy.
- The device is past its replacement date. Cover should not be assumed beyond the labeled interval.
- Insertion timing was unclear. Backup for the first seven days is required unless inserted within the first five days of a cycle, or under the switching rules in the labeling.
- Pregnancy symptoms are present. Test first and interpret the result before adjusting anything else.
Drug interactions worth flagging
Strong cytochrome P450 3A4 inducers can lower progestin concentrations. Rifampin, several older anticonvulsants, certain antiretrovirals, bosentan, and St. John’s wort are the commonly cited examples. The labeling advises counseling on a backup or alternative method during use of an interacting drug and for a period afterward. The CDC’s US Medical Eligibility Criteria for Contraceptive Use gives category guidance for these combinations and should be checked against the current edition rather than memory.
Body weight is a frequent question. Labeling notes that serum etonogestrel concentrations are inversely related to body weight and decline over time, but it does not direct a shortened replacement interval. Avoid telling patients that a higher weight means the implant has worn off early.
The non-palpable implant
If the rod cannot be felt, do not remove by exploration and do not assume it was never inserted. Localization comes first. High-frequency ultrasound by an operator familiar with the device is the usual first step. The implant contains barium sulfate and is radiopaque, so two-dimensional radiography of the arm is a reasonable alternative when ultrasound is unavailable or inconclusive. MRI and etonogestrel serum assay are later options. The manufacturer maintains clinical support for localization and removal, and referral to a trained remover is appropriate when imaging is ambiguous or the device sits near neurovascular structures. Until placement is confirmed, the patient should use an additional method.
Confirming Status and Ruling Out Pregnancy
Work through a fixed sequence so nothing is skipped. First, retrieve the insertion date, arm, and lot from the record or the patient card. Second, palpate the implant and document that it was felt along its full length. Third, review the medication list for inducers started since insertion. Fourth, perform a urine pregnancy test if there is any plausible exposure, late or absent bleeding in a previously regular user, or new pelvic pain.
A positive test in a patient with an implant in situ requires prompt assessment, including consideration of ectopic pregnancy. Pelvic pain with a positive test is an urgent evaluation, not a routine follow-up. If an intrauterine pregnancy is confirmed and continues, labeling directs removal of the implant. Serum etonogestrel measurement is rarely useful for routine reassurance and is mainly reserved for localization problems or medicolegal questions.
Counseling Points That Reduce Repeat Visits
Set expectations at insertion and most of these consultations never happen. Tell patients plainly that bleeding will be unpredictable, that patterns can change at any point, and that no sensation signals the end of effectiveness. Give the replacement month in writing, on a card and in the after-visit summary, and encourage a phone reminder set by the patient in the room.
Be equally direct about what should prompt contact: a rod that can no longer be felt, a new prescription for an interacting medicine, pelvic pain, or a positive pregnancy test. Framing the discussion this way answers the underlying question behind most searches about the signs Nexplanon is wearing off without implying that symptoms carry diagnostic weight.
Removal, Replacement, and Return of Fertility
Removal is a minor procedure performed under local anesthetic through a small incision at the distal end of the rod. When a patient wants to continue the method, a new implant may be placed in the same arm, through the same incision, along the same track described in the labeling. That approach keeps scarring and chair time down.
Fertility returns rapidly. Serum etonogestrel becomes undetectable within about a week of removal, and ovulation can resume soon after. Patients who are not seeking pregnancy need a method in place at the point of removal, not a week later. For those switching to another method, the CDC’s Selected Practice Recommendations set out the timing and backup rules for each transition.
Stock Handling, Documentation, and Sourcing
Implant stock is simple to manage but easy to get wrong at the margins. Store units at controlled room temperature within the range printed on the carton, away from direct heat. Rotate by expiration date and check the sterile package before every insertion. Record the lot number and carton expiry in the procedure note alongside the arm used, the insertion site, confirmation of palpation after placement, and the date replacement is due.
Clinics that stock multiple product lines through a single account should keep contraceptive devices on the same lot-tracking discipline as injectables. Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013.
Clinic Checklist for the Patient Who Thinks the Implant Has Stopped Working
- Confirm the insertion date from the chart, card, or prior clinic.
- Palpate both ends of the rod and document the finding.
- Image before exploring if the device cannot be felt.
- Screen the medication list for enzyme-inducing drugs added since insertion.
- Test for pregnancy where exposure is plausible or bleeding has stopped unexpectedly.
- Escalate pelvic pain with a positive test for same-day assessment.
- Book replacement before the labeled interval ends, with bridging cover agreed if removal will be delayed.
Handled this way, a worried patient leaves with a date rather than a theory, and the clinic has a defensible record of what was checked. Product facts above follow current US labeling and federal contraceptive guidance; confirm specifics against the edition in force at the time of care.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.







